1,289,888 Shares in Evolus, Inc. $EOLS Purchased by Rice Hall James & Associates LLC

Rice Hall James & Associates LLC acquired a new position in Evolus, Inc. (NASDAQ:EOLS) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 1,289,888 shares of the company’s stock, valued at approximately $8,952,000. Rice Hall James & Associates LLC owned about 1.96% of Evolus at the end of the most recent reporting period.

Several other large investors have also modified their holdings of EOLS. Larson Financial Group LLC raised its holdings in shares of Evolus by 136.6% in the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after buying an additional 2,837 shares during the period. Meeder Asset Management Inc. bought a new position in Evolus in the 4th quarter valued at $34,000. Wexford Capital LP bought a new position in Evolus in the 3rd quarter valued at $37,000. Aquatic Capital Management LLC bought a new position in Evolus in the 3rd quarter valued at $48,000. Finally, State of Wyoming purchased a new stake in Evolus in the fourth quarter worth $63,000. Hedge funds and other institutional investors own 90.69% of the company’s stock.

Evolus Stock Down 4.7%

Shares of NASDAQ EOLS opened at $7.77 on Tuesday. The business has a fifty day simple moving average of $6.69 and a two-hundred day simple moving average of $5.67. The firm has a market cap of $513.21 million, a PE ratio of -14.94 and a beta of 1.35. Evolus, Inc. has a twelve month low of $3.86 and a twelve month high of $8.43.

Analyst Ratings Changes

EOLS has been the subject of a number of recent analyst reports. Wall Street Zen raised shares of Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Weiss Ratings raised shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, June 15th. Finally, BTIG Research reissued a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research report on Wednesday, June 17th. Four research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $14.50.

Evolus Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.